Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: A multicenter randomised controlled clinical trial

Abstract

ObjectivesCoupled plasma filtration adsorption (CPFA, Bellco, Italy), to remove inflammatory mediators from blood, has been proposed as a novel treatment for septic shock. This multicenter, randomised, non-blinded trial compared CPFA with standard care in the treatment of critically ill patients with septic shock.DesignProspective, multicenter, randomised, open-label, two parallel group and superiority clinical trial.Setting18 Italian adult, general, intensive care units (ICUs).ParticipantsOf the planned 330 adult patients with septic shock, 192 were randomised to either have CPFA added to the standard care, or not. The external monitoring committee excluded eight ineligible patients who were erroneously included.InterventionsCPFA was to be performed daily for 5 days, lasting at least 10 h/day.Primary and secondary outcome measuresThe primary endpoint was mortality at discharge from the hospital at which the patient last stayed. Secondary endpoints were: 90-day mortality, new organ failures and ICU-free days within 30 days.ResultsThere was no statistical difference in hospital mortality (47.3% controls, 45.1% CPFA; p=0.76), nor in secondary endpoints, namely the occurrence of new organ failures (55.9% vs 56.0%; p=0.99) or free-ICU days during the first 30 days (6.8 vs 7.5; p=0.35). The study was terminated on the grounds of futility. Several patients randomised to CPFA were subsequently found to be undertreated. An a priori planned subgroup analysis showed those receiving a CPFA dose >0.18 L/kg/day had a lower mortality compared with controls (OR 0.36, 95% CI 0.13 to 0.99).ConclusionsCPFA did not reduce mortality in patients with septic shock, nor did it positively affect other important clinical outcomes. A subgroup analysis suggested that CPFA could reduce mortality, when a high volume of plasma is treated. Owing to the inherent potential biases of such a subgroup analysis, this result can only be viewed as a hypothesis generator and should be confirmed in future studies.ClinicalTrials.govNCT00332371; ISRCTN24534559.

Detrimental Cross-Talk Between Sepsis and Acute Kidney Injury: New Pathogenic Mechanisms, Early Biomarkers and Targeted Therapies

“…This system is coupled in series with a standard RRT circuit. Some studies have shown interesting results concerning an improvement in hemodynamics, microvascular derangement and respiratory parameters during the course of CPFA [49]. 5.…”

Coupled Plasma Filtration Adsorption in Patients with a History of Kidney Transplantation: Report of Two Cases

“…The main clinical application of CPFA is the treatment of sepsis [2][3][4][5] . The hydrophobic resins in the cartridge can absorb a wide range of pro-/anti-inflammatory mediators thus allowing the removal of the inflammatory mediators responsible for the development and maintenance of septic shock and multiple organ dysfunction syndrome.…”

A Pilot Study of Selective Lipopolysaccharide Adsorption and Coupled Plasma Filtration and Adsorption in Adult Patients with Severe Sepsis

“…There is only one completed randomised trial on the use of CPFA (СOMPACT), but it did not find statistically significant increases in the survival of patients with severe sepsis, most likely due to the logistical problems and deviations in the study protocol [34]. Nevertheless, a statement about the decisive influence of the plasma volume processed during the procedure on the survival of patients with severe sepsis was brought out as a result of this result and subsequent studies.…”